|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of ABCB1 mRNA Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA] Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] |
CTD |
PMID:7476894 PMID:18474546 PMID:30830211 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:11331069 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA Cycloheximide results in increased expression of ABCC3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA Cycloheximide results in decreased expression of ABCC5 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA] |
CTD |
PMID:10585473 |
|
NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases stability multiple interactions |
ISO |
Cycloheximide results in decreased stability of ADAM17 protein cordycepin inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]; N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein] |
CTD |
PMID:36558177 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein] |
CTD |
PMID:17018608 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA] Cycloheximide results in increased expression of ADM mRNA |
CTD |
PMID:11032871 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein [Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA] |
CTD |
PMID:22483689 PMID:24705868 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression increases localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein] Cycloheximide results in increased localization of AHR protein [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] |
CTD |
PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 PMID:16226227 PMID:20570689 PMID:21807577 More...
|
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Akap6 |
A-kinase anchoring protein 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:70,184,101...70,624,369
Ensembl chr 6:70,184,175...70,619,738
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] |
CTD |
PMID:21787718 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein] Cycloheximide results in increased phosphorylation of AKT1 protein |
CTD |
PMID:12472888 PMID:28634229 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA] |
CTD |
PMID:1953764 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
decreases activity multiple interactions |
ISO EXP |
Cycloheximide results in decreased activity of ALPI protein Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein] |
CTD |
PMID:15599000 PMID:20362602 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Ank2 |
ankyrin 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:88,251,216...88,303,615
Ensembl chr 1:88,251,226...88,303,615
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 PMID:6218830 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of APAF1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA] |
CTD |
PMID:22415096 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein |
CTD |
PMID:18406487 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Areg |
amphiregulin |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA Cycloheximide results in increased expression of AREG mRNA |
CTD |
PMID:15072547 PMID:15228094 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Armc5 |
armadillo repeat containing 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:182,820,141...182,826,913
Ensembl chr 1:182,820,141...182,826,907
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] |
CTD |
PMID:12002481 PMID:20570689 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:92,120,332...92,140,790
Ensembl chr 9:92,120,306...92,136,376
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein] |
CTD |
PMID:23593480 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein] |
CTD |
PMID:18533110 PMID:23593480 PMID:24057571 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg13 |
autophagy related 13 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ATG13 protein |
CTD |
PMID:27629431 |
|
NCBI chr 3:77,647,069...77,681,028
Ensembl chr 3:77,645,790...77,681,043
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions decreases expression |
EXP |
cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein] |
CTD |
PMID:23174565 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of BACH1 protein tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein] |
CTD |
PMID:27393035 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bap1 |
BRCA1 associated deubiquitinase 1 |
multiple interactions |
ISO |
BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein] |
CTD |
PMID:37414201 |
|
NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein] |
CTD |
PMID:9790906 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:11726273 PMID:22343715 PMID:34303041 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of BCL2L1 protein alternative form Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein] |
CTD |
PMID:9326359 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l14 |
Bcl2-like 14 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein] |
CTD |
PMID:16882451 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA] |
CTD |
PMID:17203194 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] |
CTD |
PMID:11535817 PMID:12925536 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]; Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:10344722 PMID:29576526 PMID:37414201 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] |
CTD |
PMID:10344722 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Camlg |
calcium modulating ligand |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA] |
CTD |
PMID:11007951 PMID:26901245 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]] |
CTD |
PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 PMID:15860571 PMID:17295206 PMID:18222423 PMID:18636177 PMID:22343715 PMID:34303041 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein] |
CTD |
PMID:12760867 PMID:16166294 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] Cycloheximide results in increased activity of CASP8 protein |
CTD |
PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] Cycloheximide results in increased activity of CASP9 protein |
CTD |
PMID:12925536 PMID:14502240 PMID:18222423 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein] |
CTD |
PMID:6845354 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catsper4 |
cation channel, sperm associated 4 |
affects response to substance |
ISO |
CATSPER4 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 5:146,427,682...146,447,346
Ensembl chr 5:146,427,683...146,446,942
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA] |
CTD |
PMID:15314095 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbx1 |
chromobox 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCL5 mRNA Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein] |
CTD |
PMID:21055460 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCN2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA Cycloheximide results in increased expression of CCN3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccn4 |
cellular communication network factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA] |
CTD |
PMID:19238344 |
|
NCBI chr 7:98,645,238...98,677,253
Ensembl chr 7:98,645,182...98,677,248
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA Cycloheximide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]] |
CTD |
PMID:17606477 PMID:18058799 PMID:25923732 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
affects expression multiple interactions |
ISO |
Cycloheximide affects the expression of CCND3 mRNA Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA] |
CTD |
PMID:9094091 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA] |
CTD |
PMID:21393419 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein] |
CTD |
PMID:9929743 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd47 |
Cd47 molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cd8a |
CD8 subunit alpha |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDC42SE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059 Ensembl chr 1:38,836,555...38,905,059
|
|
G |
Cdca5 |
cell division cycle associated 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDCA5 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of CDCA7L protein] |
CTD |
PMID:31285264 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA] |
CTD |
PMID:12800980 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein] Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA] |
CTD |
PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 PMID:28424418 PMID:28940008 PMID:31645432 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Cycloheximide results in increased expression of CDKN2A mRNA |
CTD |
PMID:17257637 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form] |
CTD |
PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects expression |
EXP |
Cycloheximide affects the expression of CFTR mRNA |
CTD |
PMID:17290305 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA] |
CTD |
PMID:17624924 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Cycloheximide results in increased expression of CISH mRNA |
CTD |
PMID:23237828 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein] |
CTD |
PMID:7839363 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]] Cycloheximide results in decreased expression of and affects the localization of CNR1 protein |
CTD |
PMID:17041005 PMID:22258905 PMID:27513693 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16350840 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15962303 PMID:17203194 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crppa |
CDP-L-ribitol pyrophosphorylase A |
affects response to substance |
ISO |
CRPPA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 6:53,120,264...53,397,030
Ensembl chr 6:53,121,438...53,397,028
|
|
G |
Cryl1 |
crystallin, lambda 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA] |
CTD |
PMID:12112025 PMID:17295206 PMID:18636177 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein] |
CTD |
PMID:9606035 PMID:10645887 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk1d |
casein kinase 1, delta |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions decreases degradation |
ISO |
Diethylhexyl Phthalate inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]; TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr20:3,700,363...3,705,331
Ensembl chr20:3,698,733...3,707,133
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of CTNNB1 protein Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:27693619 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein] |
CTD |
PMID:8830663 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]] |
CTD |
PMID:22121136 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Cycloheximide results in decreased expression of CYP11A1 protein |
CTD |
PMID:21126571 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO EXP |
Cycloheximide results in decreased activity of CYP19A1 protein Cycloheximide results in decreased expression of CYP19A1 protein |
CTD |
PMID:16480277 PMID:21126571 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects expression increases expression multiple interactions |
EXP ISO |
Cycloheximide affects the expression of CYP1A1 mRNA Cycloheximide results in increased expression of CYP1A1 mRNA 3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 PMID:9102211 PMID:9145908 PMID:9233375 PMID:10777561 PMID:11007951 PMID:11516172 PMID:11710520 PMID:12002481 PMID:12111005 PMID:15371557 PMID:15385644 PMID:16093525 PMID:17599377 PMID:17606337 PMID:19244278 PMID:19684285 PMID:20187624 PMID:20570689 PMID:22037238 PMID:28424418 PMID:29524502 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein] |
CTD |
PMID:9145908 PMID:19684285 PMID:21867498 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:19244278 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases degradation |
ISO EXP |
(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein] |
CTD |
PMID:1968335 PMID:8531136 PMID:9143349 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA] |
CTD |
PMID:20187624 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases expression |
EXP ISO |
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A2 mRNA] Cycloheximide results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:11181506 PMID:21466820 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A23-3A1 mRNA] |
CTD |
PMID:11181506 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Dag1 |
dystroglycan 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:108,890,926...108,955,611
Ensembl chr 8:108,890,929...108,952,325
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein] |
CTD |
PMID:31276663 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
EXP |
Cycloheximide results in increased expression of DDIT4 protein [EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Deaf1 |
DEAF1 transcription factor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions decreases activity |
ISO |
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein] |
CTD |
PMID:11425850 PMID:26004626 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490
|
|
G |
Dnase1l3 |
deoxyribonuclease 1L3 |
increases expression |
ISO |
Cycloheximide results in increased expression of DNASE1L3 protein |
CTD |
PMID:15118903 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of DNM1L mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:19833194 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA |
CTD |
PMID:22483689 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein] |
CTD |
PMID:20561571 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein] |
CTD |
PMID:20561571 PMID:20716444 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA] |
CTD |
PMID:12632255 PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of EGFR mRNA Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:15228094 PMID:26368632 PMID:30237564 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA] |
CTD |
PMID:12690110 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of EGR2 mRNA |
CTD |
PMID:19350554 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [epimedokoreanin B results in increased phosphorylation of EIF2A protein]; Cycloheximide inhibits the reaction [Orlistat results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 PMID:36027945 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein] Cycloheximide inhibits the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [1,12-benzoperylene results in increased expression of EIF2AK3 mRNA]] |
CTD |
PMID:22425709 PMID:35182551 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases expression multiple interactions increases phosphorylation |
ISO |
Cycloheximide results in increased expression of EIF2S1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA Cycloheximide results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:19684285 PMID:24315374 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]] Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein] |
CTD |
PMID:22689575 PMID:25923732 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]] |
CTD |
PMID:25923732 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Elf4 |
E74 like ETS transcription factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:127,587,401...127,639,063
Ensembl chr X:127,590,650...127,630,200
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ELK1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eln |
elastin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA] |
CTD |
PMID:8997264 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ELOVL3 mRNA Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:17726147 |
|
NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Endog |
endonuclease G |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]] Cycloheximide results in decreased expression of EPAS1 protein |
CTD |
PMID:23958427 PMID:26735578 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] |
CTD |
PMID:10756076 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epyc |
epiphycan |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:32,436,620...32,474,326
Ensembl chr 7:32,436,620...32,474,135
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression increases degradation |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein |
CTD |
PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Cycloheximide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein] |
CTD |
PMID:26784903 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein] |
CTD |
PMID:24586459 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] |
CTD |
PMID:15207704 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ESRRA protein HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Ext2 |
exostosin glycosyltransferase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:79,665,414...79,798,077
Ensembl chr 3:79,665,415...79,798,059
|
|
G |
F12 |
coagulation factor XII |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein] |
CTD |
PMID:14630613 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA] |
CTD |
PMID:11876987 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases response to substance |
ISO |
Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] Cycloheximide results in increased susceptibility to FAS protein |
CTD |
PMID:8932996 PMID:12760867 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA] [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:11007951 PMID:19833194 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA] |
CTD |
PMID:12798352 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbl |
fibrillarin |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]] |
CTD |
PMID:24457827 PMID:25897075 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
EXP |
Cycloheximide results in decreased expression of FGA protein |
CTD |
PMID:444225 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
EXP |
Cycloheximide results in decreased expression of FGB protein |
CTD |
PMID:444225 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:15654655 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA] |
CTD |
PMID:12805413 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgl2 |
fibrinogen-like 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of FLT3 protein mutant form |
CTD |
PMID:32284743 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases expression |
ISO |
Cycloheximide results in increased expression of FMO3 mRNA |
CTD |
PMID:20570689 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA] Cycloheximide results in increased expression of FOS mRNA [Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA] Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein] |
CTD |
PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 PMID:15090535 PMID:15136564 PMID:20495008 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein] |
CTD |
PMID:1978808 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:4,482,168...4,485,153
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein] |
CTD |
PMID:17628625 PMID:19328227 PMID:24437944 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA] |
CTD |
PMID:19328227 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA] |
CTD |
PMID:14662774 PMID:18801729 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; Cycloheximide promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein] |
CTD |
PMID:34283317 PMID:36863560 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpaa1 |
glycosylphosphatidylinositol anchor attachment 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of GPAA1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001
|
|
G |
Grm5 |
glutamate metabotropic receptor 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein] |
CTD |
PMID:11665859 |
|
NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274
|
|
G |
Grn |
granulin precursor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of GSTA1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA] |
CTD |
PMID:16243960 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Cycloheximide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
ISO |
HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases degradation multiple interactions decreases expression |
ISO EXP |
Cycloheximide results in increased degradation of HIF1A protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein] Cycloheximide results in decreased expression of HIF1A [Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Cycloheximide affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [sodium arsenite inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; sodium arsenite inhibits the reaction [Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein] Cycloheximide results in decreased expression of HIF1A protein |
CTD |
PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 PMID:23593480 PMID:24188932 PMID:24221993 PMID:24497960 PMID:25192544 PMID:27286880 PMID:29630948 PMID:30266538 PMID:31285264 PMID:31850806 PMID:34717917 PMID:34900531 PMID:35513012 PMID:36709824 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein] Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein] Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein] |
CTD |
PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 PMID:15876423 PMID:15965080 PMID:16647178 PMID:17002867 PMID:18357586 PMID:19781563 PMID:20060010 PMID:20833156 PMID:21840424 PMID:24255720 PMID:24437944 PMID:25239868 PMID:26385185 PMID:30076913 PMID:35821281 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
increases expression |
ISO |
Cycloheximide results in increased expression of HNRNPH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein] |
CTD |
PMID:24990929 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA] |
CTD |
PMID:31927052 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Cycloheximide results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein] Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein] |
CTD |
PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 PMID:34560123 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] Cycloheximide results in decreased expression of ICAM1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] |
CTD |
PMID:12070711 PMID:16087364 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ift27 |
intraflagellar transport 27 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:109,738,622...109,754,416
Ensembl chr 7:109,738,622...109,754,416
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol] IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:2120207 PMID:26687534 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of IGFBP4 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA] Cycloheximide results in increased expression of IL10 mRNA IL10 protein results in decreased susceptibility to Cycloheximide |
CTD |
PMID:19395591 PMID:22183712 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein] |
CTD |
PMID:18310510 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] |
CTD |
PMID:18660453 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA Cycloheximide results in increased expression of IL1A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form] Cycloheximide results in increased expression of IL1B mRNA Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 PMID:26901245 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il5 |
interleukin 5 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of IL5 protein T0901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein] |
CTD |
PMID:23150660 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion increases expression decreases secretion |
ISO |
Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] Cycloheximide results in decreased secretion of IL6 protein |
CTD |
PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:19070612 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein] |
CTD |
PMID:22537771 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of IRS1 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb6 |
integrin subunit beta 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] |
CTD |
PMID:11007951 PMID:21303922 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
multiple interactions |
ISO |
ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein] |
CTD |
PMID:12925536 |
|
NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA] |
CTD |
PMID:11007951 PMID:17241155 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Ivns1abp |
influenza virus NS1A binding protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA] |
CTD |
PMID:17016628 |
|
NCBI chr13:63,427,040...63,446,701
Ensembl chr13:63,427,041...63,446,701
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases stability multiple interactions increases phosphorylation |
EXP ISO |
Cycloheximide results in increased stability of JUN protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA] Cycloheximide results in increased phosphorylation of JUN protein |
CTD |
PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kank1 |
KN motif and ankyrin repeat domains 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:222,877,622...223,074,514
|
|
G |
Kiaa0930 |
KIAA0930 homolog |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:116,067,974...116,107,678
Ensembl chr 7:116,071,447...116,107,727
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
affects response to substance |
ISO |
KREMEN1 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr14:80,081,870...80,147,489
Ensembl chr14:80,084,403...80,147,516
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:174,654,409...174,658,405
Ensembl chr 2:174,654,219...174,658,405
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein] Cycloheximide results in decreased expression of LDLR protein |
CTD |
PMID:22388943 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions decreases expression |
ISO |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein] |
CTD |
PMID:21821001 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lmo7 |
LIM domain 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783
|
|
G |
Lpxn |
leupaxin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
increases degradation multiple interactions |
ISO |
Cycloheximide results in increased degradation of MAF1 protein Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions increases activity |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA] Cycloheximide results in increased activity of MAP2K1 protein |
CTD |
PMID:23237828 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK1 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein] |
CTD |
PMID:17507666 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK3 protein TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]] Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA] Cycloheximide results in increased expression of MAPK7 mRNA |
CTD |
PMID:11007951 PMID:19684285 |
|
NCBI chr10:46,170,264...46,176,262
Ensembl chr10:46,170,167...46,176,267
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
affects response to substance |
ISO |
MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568
|
|
G |
Mbp |
myelin basic protein |
affects expression |
EXP |
Cycloheximide affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [Resveratrol co-treated with Clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein] |
CTD |
PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 PMID:35561756 More...
|
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdk |
midkine |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] Cycloheximide results in increased expression of MIR21 mRNA |
CTD |
PMID:19264808 PMID:23052036 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein |
CTD |
PMID:30849679 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA] |
CTD |
PMID:15075337 PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MMP13 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA] |
CTD |
PMID:16350840 PMID:19684285 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA] |
CTD |
PMID:26621329 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mnx1 |
motor neuron and pancreas homeobox 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:5,866,506...5,871,465
Ensembl chr 4:5,866,506...5,871,465
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of MRPS7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:23,444,326...23,585,777
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] |
CTD |
PMID:9614211 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MT1 mRNA 2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:14998373 PMID:19276070 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mtch2 |
mitochondrial carrier 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:76,830,549...76,850,189
Ensembl chr 3:76,830,413...76,850,189
|
|
G |
Mterf3 |
mitochondrial transcription termination factor 3 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of MTERF3 protein Ammonium Chloride inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein] |
CTD |
PMID:35904214 |
|
NCBI chr 7:63,826,418...63,844,747
Ensembl chr 7:63,826,427...63,844,658
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:19276070 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtmr7 |
myotubularin related protein 7 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MTMR7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr16:51,641,267...51,732,212
Ensembl chr16:51,641,190...51,732,182
|
|
G |
Mxd1 |
max dimerization protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751
|
|
G |
Mxd3 |
Max dimerization protein 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO EXP |
arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA] Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of MYC protein] |
CTD |
PMID:1696944 PMID:23593480 PMID:24457827 PMID:31285264 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] |
CTD |
PMID:15701621 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myo1d |
myosin ID |
affects response to substance |
ISO |
MYO1D gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr10:65,489,153...65,765,812
Ensembl chr10:65,489,154...65,766,349
|
|
G |
Nbr1 |
NBR1, autophagy cargo receptor |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of NBR1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein] |
CTD |
PMID:28906492 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of NEDD4 protein Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein] |
CTD |
PMID:31325559 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nefh |
neurofilament heavy chain |
decreases expression decreases degradation |
EXP |
Cycloheximide results in decreased expression of NEFH mRNA Cycloheximide results in decreased degradation of NEFH mRNA |
CTD |
PMID:1280263 PMID:19146868 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
decreases expression decreases degradation |
EXP |
Cycloheximide results in decreased expression of NEFL mRNA Cycloheximide results in decreased degradation of NEFL mRNA |
CTD |
PMID:1280263 PMID:19146868 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases degradation |
EXP |
Cycloheximide results in decreased degradation of NEFM mRNA |
CTD |
PMID:1280263 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nek2 |
NIMA-related kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein] [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein] |
CTD |
PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 PMID:25896339 PMID:27286880 PMID:27939242 PMID:34758851 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization increases expression multiple interactions |
ISO |
Cycloheximide affects the localization of NFKB1 protein Cycloheximide results in increased expression of NFKB1 mRNA Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:16637064 PMID:21146893 PMID:24457827 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation decreases expression |
ISO |
Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein] |
CTD |
PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein] |
CTD |
PMID:20495008 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein] |
CTD |
PMID:26901245 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Raloxifene Hydrochloride co-treated with 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA] |
CTD |
PMID:10760090 PMID:11007951 PMID:28138957 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
ISO EXP |
Cycloheximide results in decreased expression of NQO1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein] |
CTD |
PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:18787026 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA Cycloheximide results in increased expression of NR1H3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA] |
CTD |
PMID:21569845 PMID:31778773 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nucks1 |
nuclear casein kinase and cyclin-dependent kinase substrate 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein] |
CTD |
PMID:7662713 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form] |
CTD |
PMID:20678484 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA Cycloheximide results in increased expression of OPRK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA] |
CTD |
PMID:16434616 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA] |
CTD |
PMID:20599767 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions |
ISO |
PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] |
CTD |
PMID:20379846 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Pappa |
pappalysin |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PAPPA mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] Cycloheximide results in increased cleavage of PARP1 protein Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein] |
CTD |
PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax3 |
paired box 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pcgf1 |
polycomb group ring finger 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:115,576,165...115,587,019
Ensembl chr 4:115,583,867...115,587,008
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA] |
CTD |
PMID:9518257 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein] |
CTD |
PMID:21533478 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdcd2 |
programmed cell death 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:56,484,947...56,490,437
Ensembl chr 1:56,463,931...56,490,437
|
|
G |
Pi4ka |
phosphatidylinositol 4-kinase alpha |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:83,609,148...83,726,876
Ensembl chr11:83,609,069...83,724,080
|
|
G |
Pigh |
phosphatidylinositol glycan anchor biosynthesis, class H |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:97,874,903...97,897,188
Ensembl chr 6:97,882,903...97,897,142
|
|
G |
Pigk |
phosphatidylinositol glycan anchor biosynthesis, class K |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:241,630,021...241,715,493
Ensembl chr 2:241,630,053...241,716,134
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pilrb1 |
paired immunoglobin-like type 2 receptor beta 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr12:18,516,161...18,525,375
Ensembl chr12:18,516,156...18,525,346
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:41,142,193...41,151,967
Ensembl chr12:41,142,200...41,153,226
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]] |
CTD |
PMID:10874129 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA] |
CTD |
PMID:2477232 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA Cycloheximide results in increased expression of PLAUR mRNA |
CTD |
PMID:12070711 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pld3 |
phospholipase D family, member 3 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PLD3 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072
|
|
G |
Pln |
phospholamban |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Plp1 |
proteolipid protein 1 |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA] Cycloheximide results in increased expression of PLP1 mRNA |
CTD |
PMID:19450544 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein] |
CTD |
PMID:17216584 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pml |
PML nuclear body scaffold |
decreases degradation multiple interactions |
ISO |
Cycloheximide results in decreased degradation of PML protein modified form Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein] |
CTD |
PMID:20943951 PMID:26049103 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein] |
CTD |
PMID:18643838 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones] |
CTD |
PMID:2993719 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases expression |
ISO |
POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein] |
CTD |
PMID:27496950 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein] |
CTD |
PMID:24497960 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppan |
peter pan homolog |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:19,423,908...19,427,941
Ensembl chr 8:19,423,961...19,427,938
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of PPP1R15A protein arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein] |
CTD |
PMID:29109149 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp3cb |
protein phosphatase 3 catalytic subunit beta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:3,759,950...3,804,976
Ensembl chr15:3,760,030...3,804,981
|
|
G |
Ppp4r3b |
protein phosphatase 4, regulatory subunit 3B |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:102,917,043...102,965,210
Ensembl chr14:102,917,443...103,068,192
|
|
G |
Prdx4 |
peroxiredoxin 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Prkcb |
protein kinase C, beta |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of PRKCB mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein] |
CTD |
PMID:11118818 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein] |
CTD |
PMID:11118818 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Psmd1 |
proteasome 26S subunit, non-ATPase 1 |
multiple interactions |
ISO |
PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211
|
|
G |
Psme3 |
proteasome activator subunit 3 |
multiple interactions |
ISO |
PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:31645432 |
|
NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Cycloheximide affects the reaction [sodium arsenite affects the expression of PTEN protein]; Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:33256086 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] Cycloheximide results in increased expression of PTGS2 mRNA |
CTD |
PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 PMID:22767315 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptn |
pleiotrophin |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PTN mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA] |
CTD |
PMID:19146866 |
|
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Rabepk |
Rab9 effector protein with kelch motifs |
affects response to substance |
ISO |
RABEPK gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 3:18,061,299...18,083,191
Ensembl chr 3:18,061,574...18,083,191
|
|
G |
Rapgef1 |
Rap guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:12,898,349...13,016,234
Ensembl chr 3:12,898,266...13,013,984
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA] Cycloheximide results in increased expression of RARB mRNA |
CTD |
PMID:19450544 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of RARRES2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:20100483 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:11007951 PMID:20100483 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RBPJ protein [PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] Cycloheximide affects the localization of RELA protein |
CTD |
PMID:16637064 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein] |
CTD |
PMID:9203624 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
EXP |
Cycloheximide results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA] |
CTD |
PMID:18327666 |
|
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein] |
CTD |
PMID:23732113 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RHOC protein RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:25897075 PMID:29576526 |
|
NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
|
|
G |
Rnf168 |
ring finger protein 168 |
multiple interactions |
ISO |
RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr11:68,486,313...68,508,296
Ensembl chr11:68,486,321...68,508,277
|
|
G |
Rnf4 |
ring finger protein 4 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RNF4 protein Cycloheximide inhibits the reaction [TAK-243 affects the localization of RNF4 protein] |
CTD |
PMID:20943951 PMID:31285264 |
|
NCBI chr14:76,401,292...76,423,270
Ensembl chr14:76,401,299...76,422,566
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418 Ensembl chr12:67,562,483...67,567,418 Ensembl chr 2:67,562,483...67,567,418
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:22689575 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA] |
CTD |
PMID:22403396 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA] |
CTD |
PMID:15962303 PMID:18327666 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S100b |
S100 calcium binding protein B |
decreases expression |
EXP |
Cycloheximide results in decreased expression of S100B mRNA |
CTD |
PMID:19146868 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]] |
CTD |
PMID:16637064 |
|
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sec11c |
SEC11 homolog C, signal peptidase complex subunit |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364
|
|
G |
Serpinb9 |
serpin family B member 9 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA] |
CTD |
PMID:10681578 |
|
NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO EXP |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:11007951 PMID:12111005 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpine2 |
serpin family E member 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERPINE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Sertad2 |
SERTA domain containing 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERTAD2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein] |
CTD |
PMID:25637945 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein] |
CTD |
PMID:25128767 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sirpa |
signal-regulatory protein alpha |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:116,819,730...116,858,099
Ensembl chr 3:116,819,726...116,858,098
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein] |
CTD |
PMID:30055241 PMID:31082419 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA] |
CTD |
PMID:9020066 |
|
NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA] |
CTD |
PMID:19450544 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SLC22A4 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc25a27 |
solute carrier family 25, member 27 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC25A27 mRNA |
CTD |
PMID:20385226 |
|
NCBI chr 9:17,306,898...17,333,942
Ensembl chr 9:17,307,023...17,332,731
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [4-hydroxyisoleucine results in increased localization of SLC2A4 protein] |
CTD |
PMID:22610671 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]] |
CTD |
PMID:11123204 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA] |
CTD |
PMID:18020946 |
|
NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:108,333,381...108,337,553
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC3A2 mRNA |
CTD |
PMID:26621329 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC5A5 mRNA |
CTD |
PMID:17164311 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
|
|
G |
Smn1 |
survival of motor neuron 1, telomeric |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form] |
CTD |
PMID:17064354 |
|
NCBI chr 2:31,490,018...31,501,065
Ensembl chr 2:31,490,015...31,501,060
|
|
G |
Snw1 |
SNW domain containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:107,095,450...107,119,536
Ensembl chr 6:107,095,457...107,119,536
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions increases expression |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA Cycloheximide results in increased expression of SOCS1 mRNA |
CTD |
PMID:16849584 PMID:23237828 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA] Cycloheximide results in increased expression of SOCS2 mRNA |
CTD |
PMID:15371557 PMID:23237828 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SOCS3 mRNA Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA] |
CTD |
PMID:23237828 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS4 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr15:20,523,406...20,537,889
Ensembl chr15:20,523,183...20,542,494
|
|
G |
Socs5 |
suppressor of cytokine signaling 5 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS5 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr 6:7,481,039...7,512,644
Ensembl chr 6:7,481,095...7,514,834
|
|
G |
Socs6 |
suppressor of cytokine signaling 6 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS6 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr18:82,111,866...82,139,193
Ensembl chr18:82,111,827...82,139,219
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS7 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr10:82,352,159...82,388,829
Ensembl chr10:82,351,680...82,388,830
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2] Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA] |
CTD |
PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sort1 |
sortilin 1 |
multiple interactions increases degradation |
EXP ISO |
SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]] Cycloheximide results in increased degradation of SORT1 protein mutant form |
CTD |
PMID:22555848 PMID:24986865 PMID:25805502 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
multiple interactions |
ISO |
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
[sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Cycloheximide results in decreased expression of SQSTM1 protein]; Cycloheximide promotes the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]] |
CTD |
PMID:31781319 PMID:34405320 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
increases localization |
EXP |
Cycloheximide results in increased localization of SRC protein |
CTD |
PMID:10401681 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srr |
serine racemase |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] |
CTD |
PMID:24012499 |
|
NCBI chr10:59,769,563...59,786,688
Ensembl chr10:59,769,571...59,787,011
|
|
G |
Ssbp1 |
single stranded DNA binding protein 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SSBP1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135
|
|
G |
St18 |
ST18 C2H2C-type zinc finger transcription factor |
increases expression |
ISO |
Cycloheximide results in increased expression of ST18 mRNA |
CTD |
PMID:23236509 |
|
NCBI chr 5:12,582,493...12,914,221
Ensembl chr 5:12,584,110...12,671,790
|
|
G |
St8sia1 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA Cycloheximide results in increased expression of ST8SIA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:175,782,989...175,921,338
Ensembl chr 4:175,789,947...175,920,708
|
|
G |
Stk3 |
serine/threonine kinase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:66,052,345...66,323,233
|
|
G |
Stx2 |
syntaxin 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:27,678,744...27,714,751
Ensembl chr12:27,689,819...27,714,751
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA] |
CTD |
PMID:16308312 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
|
|
G |
Supt4h1 |
SPT4 homolog, DSIF elongation factor subunit |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:72,539,323...72,545,582
Ensembl chr10:72,539,382...72,545,831
|
|
G |
Synpo |
synaptopodin |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA Cycloheximide results in increased expression of SYNPO mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tacc1 |
transforming, acidic coiled-coil containing protein 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA Cycloheximide results in increased expression of TACC1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr16:66,812,232...66,895,736
Ensembl chr16:66,812,295...66,895,733
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions decreases expression |
ISO |
Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein] |
CTD |
PMID:24477737 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tas2r106 |
taste receptor, type 2, member 106 |
multiple interactions |
ISO |
TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15087236 |
|
NCBI chr 4:165,313,210...165,314,133
Ensembl chr 4:165,313,210...165,314,133
|
|
G |
Tbx3 |
T-box transcription factor 3 |
increases expression |
ISO |
cycloheximide co-treated with all-trans-retinoic acid increases expression of TBX3 mRNA in melanoma cells |
RGD |
PMID:22535523 |
RGD:151361117 |
NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
|
|
G |
Testin |
testin gene |
multiple interactions decreases expression decreases secretion |
EXP |
Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein] Cycloheximide results in decreased expression of TESTIN mRNA Cycloheximide results in decreased secretion of TESTIN protein |
CTD |
PMID:11090432 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
decreases stability multiple interactions |
ISO |
Cycloheximide results in decreased stability of TFAP2A protein LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein] |
CTD |
PMID:36576707 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA] Cycloheximide results in increased expression of TFF1 mRNA |
CTD |
PMID:15072547 PMID:20875696 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Cycloheximide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases activity |
EXP ISO |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] Cycloheximide results in decreased activity of TGFB1 protein |
CTD |
PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein] |
CTD |
PMID:31381904 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA] |
CTD |
PMID:16723184 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tia1 |
TIA1 cytotoxic granule-associated RNA binding protein |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] |
CTD |
PMID:19171178 PMID:22555848 |
|
NCBI chr 4:118,852,765...118,883,252
Ensembl chr 4:118,852,837...118,880,586
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
multiple interactions decreases expression |
ISO |
Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] Cycloheximide results in decreased expression of TIMM17A protein |
CTD |
PMID:24315374 |
|
NCBI chr13:46,731,117...46,742,604
Ensembl chr13:46,730,660...46,742,655
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases response to substance |
EXP |
TIMP1 protein results in decreased susceptibility to Cycloheximide |
CTD |
PMID:15860571 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions increases expression |
ISO |
AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA] |
CTD |
PMID:12147270 |
|
NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] Cycloheximide results in decreased expression of TJP1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154
|
|
G |
Tmem263 |
transmembrane protein 263 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of TMEM263 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:18,610,151...18,628,311
Ensembl chr 7:18,610,149...18,628,534
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance multiple interactions |
ISO EXP |
TNF protein results in increased susceptibility to Cycloheximide [TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 PMID:15701621 PMID:16077199 PMID:17337591 PMID:18182247 PMID:21146893 PMID:22121136 PMID:22241084 PMID:22258905 PMID:22319556 PMID:22555848 PMID:24068670 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip1 |
TNF alpha induced protein 1 |
multiple interactions |
ISO |
TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr10:63,417,774...63,432,466
Ensembl chr10:63,417,775...63,432,466
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:21146893 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein] Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA] |
CTD |
PMID:11212279 PMID:27484784 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:157,123,183...157,168,421
Ensembl chr 5:157,123,185...157,168,421
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA] |
CTD |
PMID:11007951 PMID:18222423 PMID:22343715 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnc1 |
troponin C1, slow skeletal and cardiac type |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:6,400,801...6,405,634
Ensembl chr16:6,402,171...6,405,634
|
|
G |
Tp53 |
tumor protein p53 |
increases response to substance multiple interactions decreases expression increases degradation |
ISO EXP |
TP53 mutant form results in increased susceptibility to Cycloheximide Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein] Cycloheximide results in decreased expression of TP53 protein |
CTD |
PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 PMID:27993609 PMID:31645432 PMID:35821281 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA] Cycloheximide results in decreased expression of TP53I11 mRNA |
CTD |
PMID:19333544 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form] |
CTD |
PMID:20043870 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tubgcp3 |
tubulin gamma complex component 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:76,851,859...76,912,499
Ensembl chr16:76,851,810...76,912,499
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA] |
CTD |
PMID:12663510 PMID:15652504 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tymp |
thymidine phosphorylase |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of TYMP protein salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]] |
CTD |
PMID:30796972 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions decreases expression |
ISO |
cinobufagin promotes the reaction [Cycloheximide results in decreased expression of TYMS protein]; Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA] |
CTD |
PMID:17172411 PMID:35427566 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein] [resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein] |
CTD |
PMID:14717847 PMID:29621941 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein] |
CTD |
PMID:15545831 |
|
NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA Cycloheximide results in decreased expression of UGT1A1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:22846377 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ULK1 protein Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
multiple interactions |
ISO |
USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein] |
CTD |
PMID:35821281 |
|
NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
ISO |
VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:12892526 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
EXP ISO |
Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form] [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA Cycloheximide results in increased expression of VEGFA mRNA Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA] |
CTD |
PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Virma |
vir like m6A methyltransferase associated |
affects response to substance |
ISO |
VIRMA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 5:24,961,208...25,024,660
Ensembl chr 5:24,960,778...25,023,341
|
|
G |
Vldlr |
very low density lipoprotein receptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Vsnl1 |
visinin-like 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479
|
|
G |
Wwox |
WW domain-containing oxidoreductase |
affects response to substance |
ISO |
WWOX gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr19:42,432,141...43,360,278
Ensembl chr19:42,432,152...43,359,391
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
G |
Yme1l1 |
YME1-like 1 ATPase |
multiple interactions |
ISO |
YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr17:85,287,607...85,326,068
Ensembl chr17:85,287,554...85,326,335
|
|
|
G |
Hoxb9 |
homeo box B9 |
multiple interactions |
ISO |
[Penicillins co-treated with Streptomycin] results in increased expression of HOXB9 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Pax3 |
paired box 3 |
multiple interactions |
ISO |
[Penicillins co-treated with Streptomycin] results in increased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Tcf15 |
transcription factor 15 |
multiple interactions |
ISO |
[Penicillins co-treated with Streptomycin] results in increased expression of TCF15 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Streptomycin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:17699551 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Uncx |
UNC homeobox |
multiple interactions |
ISO |
[Penicillins co-treated with Streptomycin] results in increased expression of UNCX mRNA |
CTD |
PMID:31711903 |
|
NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300
|
|